https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47089 Wed 14 Dec 2022 09:30:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43376 5 years. Conclusions: Use of potentially inappropriate medications in Australian nursing home residents with advanced dementia is common. A greater understanding of the rationale that underpins prescribing of medications is required.]]> Thu 15 Sep 2022 15:53:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51680 Thu 14 Sep 2023 15:52:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30664 Thu 02 May 2019 11:11:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48253 Sat 11 Mar 2023 12:51:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46409 Mon 21 Nov 2022 11:52:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39204 Fri 27 May 2022 09:45:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46587 Misuse is not the main problem) contextualised misuse as a relatively minor concern compared with pain control and toxicity, and highlighted underlying systemic factors, including limitations in continuity of care and doctor expertise. Theme 2 (‘A different mindset’ for cancer pain) captured participants’ relative comfort in prescribing opioids for pain in cancer versus non-cancer contexts, and acknowledgement that compassion and greater perceived community acceptance were driving factors, in addition to scientific support for mechanisms and clinical efficacy. Participant attitudes towards prescribing for people with cancer versus non-cancer pain differed most when cancer was in the palliative phase, when they were unconcerned by misuse. Participants were equivocal about the risk–benefit ratio of long-term opioid therapy in the chronic phase of cancer, and were reluctant to prescribe for disease-free survivors. Theme 3 (‘The question is always, ‘how lazy have you been?’) captured participants’ acknowledgement that they sometimes prescribed opioids for cancer pain as a default, easier option compared with more holistic pain management. Conclusions: Findings highlight the role of specific clinical considerations in distinguishing risk of opioid misuse in the cancer versus non-cancer population, rather than diagnosis per se. Further efforts are needed to ensure continuity of care where opioid prescribing is shared. Greater evidence is needed to guide opioid prescribing in disease-free survivors and the chronic phase of cancer, especially in the context of new treatments for metastatic disease.]]> Fri 25 Nov 2022 14:52:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38006 Fri 23 Jul 2021 15:05:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42248 r = − 0.437; p < 0.001 at 12 months). Changes within QUALID and EQ-5D-5L across the same follow-up periods were also correlated (r = − 0.266; p = 0.005). The regression analyses support these findings. Conclusion: Whilst these quality of life instruments demonstrated moderate correlation, the EQ-5D-5L does not appear to capture all aspects of quality of life that are relevant to people with advanced dementia and we cannot recommend the use of this instrument for use within this population. The QUALID appears to be a more suitable instrument for measuring HRQOL in people with severe dementia, but is not preference-based, which limits its application in economic evaluations of dementia care.]]> Fri 19 Aug 2022 12:03:27 AEST ]]>